Updates are available Correction dated 2018-01-04
Click to view Correction: https://doi.org/10.1007/s40258-017-0364-4
-
Authors
Peters, Michel L.
de Meijer, Claudine
Wyndaele, Dirk
Noordzij, Walter
Leliveld-Kors, Annemarie M.
van den Bosch, Joan
van den Berg, Pieter H.
Baka, Agni
Gaultney, Jennifer G. http://orcid.org/0000-0002-3322-1075
-
Funding
Funding for this research was provided by:
Bayer B.V.
- License Information
-
More Information
Article History
First Online: 2 September 2017
Change Date: 4 January 2018
Change Type: Correction
Change Details: The article Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer, written by Michel L. Peters, Claudine de Meijer, Dirk Wyndaele, Walter Noordzij, Annemarie M. Leliveld-Kors, Joan van den Bosch, Pieter H. van den Berg, Agni Baka, Jennifer G. Gaultney was originally published electronically on the publisher’s internet portal (currently SpringerLink) on 2nd September, 2017 without open access.
Compliance with Ethical Standards
:
: Mapi Group was financially supported by Bayer B. V. to perform the study.
: M. L. Peters and J. G. Gaultney are Mapi Group employees and served as paid consultants to Bayer during the conduct of this study; A. Baka was a Mapi Group employee at the time of the study and served as a paid consultant to Bayer during the conduct of this study; C. de Meijer is a Bayer employee; D. Wyndaele was consulted by Bayer in advisory boards; W. Noordzij was consulted by Bayer in an advisory board; A. M. Leliveld-Kors was consulted by Bayer and Astellas in advisory boards; J. van den Bosch was consulted by Bayer in advisory boards; and H. P. van den Berg was consulted by Bayer in advisory boards.
